The type 2 diabetes space across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to more than double in value from $26.8 billion in 2016 to around $64 billion by 2026. While the global T2D market is crowded with inexpensive generics and marked by a late-stage pipeline filled with me-too drugs, the market is expected to grow at a strong compound annual growth rate of 8.4%, according to research and consulting firm GlobalData.

The company's latest report reveals that the dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.

Current and future leaders in the type 2 diabetes space during the forecast period include Novo Nordisk, Astra Zeneca, Merck, Eli Lilly/BI, Takeda, Johnson & Johnson, Sanofi, and Intarcia Therapeutics. All of these companies have either late-stage pipeline products or very recently marketed products that have the potential to significantly strengthen their company's portfolios.

Jesus Cuaron, Ph.D., PPM, Managing Healthcare Analyst at GlobalData, explains: 'All currently available treatments for type 2 diabetes are initially effective and reduce complication rates, but they lack the ability to maintain glycemic control in the long term because of the progressive nature of pancreatic β-cell dysfunction. This represents one of the highest unmet needs in the type 2 diabetes space and demonstrates that the market has a significant growth opportunity for new patent-protected products that successfully address underlying disease pathology, cardiovascular concerns, or compliance issues.'

Overall, the ever-increasing prevalence of diabetes, along with the increased usage of anti-diabetic drugs with non-glycemic benefits, will lead to significant growth of the type 2 diabetes market.

- Information based on GlobalData's report: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026.

GlobalData plc published this content on 11 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 August 2017 10:26:08 UTC.

Original documenthttps://www.globaldata.com/type-2-diabetes-market-double-64-billion-2026/

Public permalinkhttp://www.publicnow.com/view/A2386F7100DCCB789B300764C73814BB0E0D875E